Marinomed’s innovative anti-viral nasal spray that has been proven clinically effective against respiratory viruses has now been authorized for the Moroccan market. The product reduces the reproduction and spread of viruses on the nasal mucosa and is based on Marinomed’s proprietary technology platform Mavirex®. As a result, Marinomed has now succeeded in licensing the over-the-counter antiviral treatment in a total of 39 countries – while, at the same time, initiating work on the development of new products.
08. 03. 2013